Literature DB >> 26200682

The Importance of a Minimal Tumor-Free Resection Margin in Locally Recurrent Rectal Cancer.

Wijnand J Alberda1, Cornelis Verhoef, Marguerite E I Schipper, Joost J Nuyttens, Joost Rothbarth, Johannes H W de Wilt, Jabobus W A Burger.   

Abstract

BACKGROUND: The importance of the circumferential resection margin has been demonstrated in primary rectal cancer, but the role of the minimal tumor-free resection margin in locally recurrent rectal cancer is unknown.
OBJECTIVE: The purpose of this work was to evaluate the prognostic importance of a minimal tumor-free resection margin in locally recurrent rectal cancer.
DESIGN: This was a single-institution, retrospective study. SETTINGS: This study was conducted in a tertiary referral hospital. PATIENTS: Based on the final pathology report, surgically treated patients with locally recurrent rectal cancer between 1990 and 2013 were divided into 4 groups: 1) tumor-free margins of >2 mm, 2) tumor-free margins of >0 to 2 mm, 3) microscopically involved margins, and 4) macroscopically involved margins. MAIN OUTCOME MEASURES: Local control and overall survival were the main outcome measures.
RESULTS: A total of 174 patients with a median follow-up of 27 months (range, 0-144 months) were eligible for analysis. There was a significant difference in 5-year local re-recurrence-free survival in favor of 41 patients with tumor-free margins of >2 mm compared with 34 patients with tumor-free margins of >0 to 2 mm (80% vs 62%; p = 0.03) and a significant difference in 5-year overall survival (60% vs 37%; p = 0.01). The 5-year local re-recurrence-free and overall survival rates for 55 patients with microscopically involved margins were 28% and 16%, and for 20 patients with macroscopically involved margins the rates were 0% and 5%. On multivariable analysis, tumor-free margins of >0 to 2 mm were independently associated with higher re-recurrence rates (HR, 2.76 (95% CI, 1.06-7.16)) and poorer overall survival (HR, 2.57 (95% CI, 1.27-5.21)) compared with tumor-free margins of >2 mm. LIMITATIONS: This study was limited by its retrospective nature.
CONCLUSIONS: Resection margin status is an independent prognostic factor for re-recurrence rate and overall survival in surgically treated, locally recurrent rectal cancer. In complete resections, patients with tumor-free resection margins of >0 to 2 mm have a higher re-recurrence rate and a poorer overall survival than patients with tumor-free resection margins of >2 mm.

Entities:  

Mesh:

Year:  2015        PMID: 26200682     DOI: 10.1097/DCR.0000000000000388

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

1.  Factors associated with the location of local rectal cancer recurrence and predictors of survival.

Authors:  Peng Du; John P Burke; Wisam Khoury; Ian C Lavery; Ravi P Kiran; Feza H Remzi; David W Dietz
Journal:  Int J Colorectal Dis       Date:  2016-02-10       Impact factor: 2.571

2.  Use of Image-Guided Surgical Navigation during Resection of Locally Recurrent Rectal Cancer.

Authors:  Harald C Groen; Anne G den Hartog; Wouter J Heerink; Koert F D Kuhlmann; Niels F M Kok; Ruben van Veen; Marijn A J Hiep; Petur Snaebjornsson; Brechtje A Grotenhuis; Geerard L Beets; Arend G J Aalbers; Theo J M Ruers
Journal:  Life (Basel)       Date:  2022-04-27

3.  Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II).

Authors: 
Journal:  BJS Open       Date:  2021-05-07

4.  Endoscopic detection of cancer with lensless radioluminescence imaging and machine vision.

Authors:  Silvan Türkcan; Dominik J Naczynski; Rosalie Nolley; Laura S Sasportas; Donna M Peehl; Guillem Pratx
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

5.  Lateral Lymph Node Metastases in Locally Advanced Low Rectal Cancers May Not Be Treated Effectively With Neoadjuvant (Chemo)Radiotherapy Only.

Authors:  Anouck Haanappel; Hidde M Kroon; Dennis P Schaap; Sergei Bedrikovetski; Nagendra N Dudi-Venkata; Hong X Lee; Michelle L Thomas; Jianliang Liu; Maxime J M van der Valk; Harm J T Rutten; Geerard L Beets; Miranda Kusters; Tarik Sammour
Journal:  Front Oncol       Date:  2019-12-03       Impact factor: 6.244

6.  Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible.

Authors:  Esmée A Dijkstra; Véronique E M Mul; Patrick H J Hemmer; Klaas Havenga; Geke A P Hospers; Christina T Muijs; Boudewijn van Etten
Journal:  Ann Surg Oncol       Date:  2021-05-22       Impact factor: 5.344

7.  MRI tumour regression grade in locally recurrent rectal cancer.

Authors:  Eva L K Voogt; Stefi Nordkamp; Desley M G I van Zoggel; Alette W Daniëls-Gooszen; Grard A P Nieuwenhuijzen; Johanne G Bloemen; Geert-Jan Creemers; Jeltsje S Cnossen; Gesina van Lijnschoten; Jacobus W A Burger; Harm J T Rutten; Joost Nederend
Journal:  BJS Open       Date:  2022-05-02

8.  Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer.

Authors:  An-Sofie E Verrijssen; Wim J F Dries; Jeltsje S Cnossen; Jacqueline Theuws; Heike M U Peulen; Hetty A van den Berg; Dorien C Rijkaart; Eva L K Voogt; Inger-Karine Kolkman-Deurloo; Joost Nuyttens; Harm J T Rutten; Jacobus W A Burger; Cathryn Huibregtse Bimmel-Nagel
Journal:  J Contemp Brachytherapy       Date:  2022-07-21

9.  Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer.

Authors:  Rosa M Jimenez-Rodriguez; Jonathan B Yuval; Charles-Etienne Gabriel Sauve; Isaac Wasserman; Piyush Aggarwal; Paul B Romesser; Christopher H Crane; Rona Yaeger; Andrea Cercek; Jose G Guillem; Martin R Weiser; Iris H Wei; Maria Widmar; Garrett M Nash; Emmanouil P Pappou; Julio Garcia-Aguilar; Marc J Gollub; Philip B Paty; J Joshua Smith
Journal:  Int J Colorectal Dis       Date:  2021-07-22       Impact factor: 2.796

Review 10.  The complementary value of intraoperative fluorescence imaging and Raman spectroscopy for cancer surgery: combining the incompatibles.

Authors:  L J Lauwerends; H Abbasi; T C Bakker Schut; P B A A Van Driel; J A U Hardillo; I P Santos; E M Barroso; S Koljenović; A L Vahrmeijer; R J Baatenburg de Jong; G J Puppels; S Keereweer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-01       Impact factor: 10.057

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.